Lupin settles patent infringement dispute with Astellas, to continue selling overactive bladder drug Mirabegron

Lupin settles patent infringement dispute with Astellas, to continue selling overactive bladder drug Mirabegron

  • Business
  • February 10, 2026
  • No Comment
  • 0

Under the agreement, Lupin will pay Astellas $90 million, which includes a prepaid option payment of $75 million, and a prepaid per unit license fee for each unit of its product sold through September 2027

Related post

Leave a Reply

Your email address will not be published. Required fields are marked *